Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting HER2-positive breast cancer: advances and future directions
Sandra M. Swain, Mythili Shastry, Erika Hamilton
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 2, pp. 101-126
Open Access | Times Cited: 527

Showing 1-25 of 527 citing articles:

Deciphering breast cancer: from biology to the clinic
Emma Nolan, Geoffrey J. Lindeman, Jane E. Visvader
Cell (2023) Vol. 186, Iss. 8, pp. 1708-1728
Open Access | Times Cited: 326
Exploring treatment options in cancer: Tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 155
Nanoparticle‐Based Photothermal Therapy for Breast Cancer Noninvasive Treatment
Yao Xiong, Yan Rao, Jiawei Hu, et al.
Advanced Materials (2023)
Closed Access | Times Cited: 81
Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy
Mohammad Chehelgerdi, Matin Chehelgerdi, Milad Khorramian‐Ghahfarokhi, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 62
Mechanisms of Resistance to Antibody–Drug Conjugates
Rachel O. Abelman, Bogang Wu, Laura M. Spring, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1278-1278
Open Access | Times Cited: 52
Targeting cytokine and chemokine signaling pathways for cancer therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 49
Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer
Moumita Kundu, Ramesh Butti, Venketesh K. Panda, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 38
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
Antonio Marra, Sarat Chandarlapaty, Shanu Modi
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 185-202
Closed Access | Times Cited: 37
Protein neddylation and its role in health and diseases
Shizhen Zhang, Qing Yu, Zhijian Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 34
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 29
Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway
Muhammad Tufail, Jia-Ju Hu, Jie Liang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 25
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance
Jing Wang, Baizhou Li, Meng Luo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 24
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Javier Cortés, Sara A. Hurvitz, Seock‐Ah Im, et al.
Nature Medicine (2024) Vol. 30, Iss. 8, pp. 2208-2215
Open Access | Times Cited: 21
Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies
Nating Xiong, Heming Wu, Zhikang Yu
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 19
A Comprehensive Review of HER2 in Cancer Biology and Therapeutics
Xiaoqing Cheng
Genes (2024) Vol. 15, Iss. 7, pp. 903-903
Open Access | Times Cited: 19
Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions
Rohan Kalyan Rej, Joyeeta Roy, Srinivasa Rao Allu
Cancers (2024) Vol. 16, Iss. 3, pp. 552-552
Open Access | Times Cited: 18
Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers
Elizabeth S. Rubin, Khine Shan, Shivani Dalal, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1064-1064
Open Access | Times Cited: 16
HER2-Positive Breast Cancer Treatment and Resistance
Jamunarani Veeraraghavan, Carmine De Angelis, Carolina Gutiérrez, et al.
Advances in experimental medicine and biology (2025), pp. 495-525
Closed Access | Times Cited: 2
Highly Sensitive Detection and Molecular Subtyping of Breast Cancer Cells Using Machine Learning-assisted SERS Technology
Xinyu Miao, Lei Xu, Li Xian Sun, et al.
Nano Biomedicine and Engineering (2025)
Open Access | Times Cited: 2
Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment
Harshini Swaminathan, K. Saravanamurali, Sangilimuthu Alagar Yadav
Medical Oncology (2023) Vol. 40, Iss. 8
Closed Access | Times Cited: 32
ADCdb: the database of antibody–drug conjugates
Liteng Shen, Xiuna Sun, Zhen Chen, et al.
Nucleic Acids Research (2023) Vol. 52, Iss. D1, pp. D1097-D1109
Open Access | Times Cited: 31
Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer
Bi Lian, Xiaosong Chen, Kunwei Shen
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 23
Recent trends and advances in novel formulations as an armament in Bcl-2/Bax targeted breast cancer
Shaikh Samia, Padakanti Sandeep Chary, Omar M. Khan, et al.
International Journal of Pharmaceutics (2024) Vol. 653, pp. 123889-123889
Closed Access | Times Cited: 14
Trastuzumab deruxtecan in breast cancer
Miguel Martín, Atanasio Pandiella, Emilio Vargas, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 198, pp. 104355-104355
Open Access | Times Cited: 14
Research Progress of SN38 Drug Delivery System in Cancer Treatment
Qing-rui Qi, Huan Tian, Baosen Yue, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 945-964
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top